Search Site

Trends banner

‘Wadeem’ sold out for $1.49bn

This is the highest Abu Dhabi real-estate release to date.

Tesla Q2 sales down 13.5%

Shares rally after the disclosure, better than some forecasts.

TomTom cuts 300 jobs

The firm said it was realigning its organization as it embraces AI.

Aldar nets $953m in sales at Fahid

Aldar said 42 percent of the buyers are under the age of 45.

Qualcomm to Alphawave for $2.4 bn

The deal makes Alphawave the latest tech company to depart London.

Drug firms urged to seek UAE advance nod for products

Dr. Amin Hussein Al Amiri
  • Factories in UAE can start manufacturing procedures and apply for marketing approval for similar products
  • Local manufacturers can market their products in the UAE soon after expiry of the protection period for innovative products

DUBAI:  International pharmaceutical companies have been asked by the UAE to apply for marketing approval of their products in the emirates before being approved in the country of manufacture.

This will allow health authorities a pre-study of the file to issue the marketing approval in the UAE for innovative products and rare medicines once they are approved by one of reference authorities.

Such an approval was made by the Ministry of Health and Prevention (MoHAP) in the case of GSK’s Sotrovimab drug for the treatment of some cases of Covid-19 and Amgen’s LUMAKRAS for the treatment of advanced lung cancer in May and June this year, said Dr. Amin Hussein Al Amiri, Assistant Undersecretary for Public Health Policy and Licensing, and Chairperson of the Pharmaceutical Board of Trustees.

A MoHAP press release said factories in UAE can start manufacturing procedures and apply for marketing approval for similar products during the two years preceding the end of the protection period for the innovative product, Al Amiri told a meeting of the Board of Trustees.

Local manufacturers can grab this opportunity and market their products in the UAE soon after the expiry of the protection period for innovative products.

Also discussed was MoHAP’s decision granting innovative medicines protection for its data for eight years. Such a decision would contribute to attracting innovative medicines to the country, enhancing the healthcare sector with curative and preventive solutions that serve the interests of patients, and support medical tourism, the press release said.